Robert M. Davis is the new Chairman of Merck
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
CGHS would give robust coverage to pensioners and with new innovations and practices
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
The move will add new global talent to Cytel’s Strategic Consulting group
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Subscribe To Our Newsletter & Stay Updated